Loading
Life sciences · Journal article
Current Problems in Cancer · September 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Oncoproteins, products of oncogenes, are critical drivers of malignant transformation and tumor progression by dysregulating cellular growth, differentiation, and survival pathways. This study aims to summarize the significant achievements in oncoprotein-targeted precision cancer therapy, delineate the persistent challenges hindering its broader application, and explore promising future directions for overcoming these hurdles and expanding the therapeutic impact. This review uses a systematic approach to identify, select, and synthesize relevant literature from various electronic databases. The search includes terms like "oncoprotein," "tumor protein," "precision cancer therapy," "molecular therapy," and "cancer." Precision cancer therapy, guided by the identification of oncoproteins, has yielded remarkable successes, notably with inhibitors targeting BCR-ABL in chronic myeloid leukemia, EGFR in lung cancer, and HER2 in breast cancer. Despite these successes, significant challenges remain, including the emergence of acquired drug resistance, tumor heterogeneity, and the lack of actionable oncoproteins in many cancer types. Future directions involve developing next-generation inhibitors, exploring combination therapies to circumvent resistance, and leveraging advanced genomic and proteomic profiling to uncover novel targets.